Logo image of MPH.CA

MEDICURE INC (MPH.CA) Stock Price, Forecast & Analysis

Canada - TSX Venture Exchange - TSX-V:MPH - CA58469E4085 - Common Stock

1.14 CAD
-0.06 (-5%)
Last: 1/7/2026, 7:00:00 PM

MPH.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap11.90M
Revenue(TTM)26.21M
Net Income(TTM)-3.43M
Shares10.44M
Float7.63M
52 Week High1.43
52 Week Low0.63
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.33
PEN/A
Fwd PEN/A
Earnings (Next)04-27 2026-04-27
IPO1999-03-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MPH.CA short term performance overview.The bars show the price performance of MPH.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

MPH.CA long term performance overview.The bars show the price performance of MPH.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20

The current stock price of MPH.CA is 1.14 CAD. In the past month the price decreased by -8.8%. In the past year, price decreased by -2.56%.

MEDICURE INC / MPH Daily stock chart

MPH.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 517.64M
EDT.CA SPECTRAL MEDICAL INC N/A 401.93M
HBP.CA HELIX BIOPHARMA CORP N/A 170.33M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 79.24M
COV.CA COVALON TECHNOLOGIES LTD 26.14 50.54M
MBX.CA MICROBIX BIOSYSTEMS INC N/A 33.36M
RVX.CA RESVERLOGIX CORP N/A 28.73M
BCT.CA BRIACELL THERAPEUTICS CORP N/A 18.59M
HEM.CA HEMOSTEMIX INC N/A 16.96M
CSCI.CA COSCIENS BIOPHARMA INC N/A 9.19M
QPT.CA QUEST PHARMATECH INC N/A 6.77M
KNE.CA KANE BIOTECH INC N/A 6.69M

About MPH.CA

Company Profile

MPH logo image Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.

Company Info

MEDICURE INC

1250 Waverley Street

Winnipeg MANITOBA R3T 6C6 CA

CEO: Albert D. Friesen

Employees: 23

MPH Company Website

MPH Investor Relations

Phone: 12044877412

MEDICURE INC / MPH.CA FAQ

Can you describe the business of MEDICURE INC?

Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.


What is the current price of MPH stock?

The current stock price of MPH.CA is 1.14 CAD. The price decreased by -5% in the last trading session.


Does MPH stock pay dividends?

MPH.CA does not pay a dividend.


What is the ChartMill rating of MEDICURE INC stock?

MPH.CA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the valuation of MEDICURE INC (MPH.CA) based on its PE ratio?

MEDICURE INC (MPH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.33).


What is the ownership structure of MEDICURE INC (MPH.CA)?

You can find the ownership structure of MEDICURE INC (MPH.CA) on the Ownership tab.


MPH.CA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to MPH.CA. When comparing the yearly performance of all stocks, MPH.CA is a bad performer in the overall market: 76.43% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MPH.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MPH.CA. While MPH.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MPH.CA Financial Highlights

Over the last trailing twelve months MPH.CA reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -68.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -12.83%
ROE -19.81%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%-279.68%
Sales Q2Q%56.6%
EPS 1Y (TTM)-68.69%
Revenue 1Y (TTM)24.3%

MPH.CA Forecast & Estimates


Analysts
Analysts40
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

MPH.CA Ownership

Ownership
Inst Owners23.1%
Ins Owners26.42%
Short Float %N/A
Short RatioN/A